




ASCO GU 2024

Güncelleme

24-25 Mayıs 2024

Double Tree by Hilton, Adana



İlk Gün 24 Mayıs 2024 Cuma	
13:45 - 14:00	AÇILIŞ KONUŞMALARI Dr. Atilla Arıdoğan, Dr. Cenk Yücel Bilen
14:00 - 15:30	Mesane Kanseri Oturumu Oturum Başkanları: Dr. Zühtü Tansuğ - Dr. Sinan Sözen
14:00 - 14:15	Mesane Kanseri Patoloji Güncellemesi- Varyant Histolojiler Dr. Şeyda Erdoğan
14:15 - 14:30	Radikal Sistektomi - Açık vs Robotik Dr. Saadettin Eskiçorapçı
14:30 - 14:35	Case Presentation Dr. Fatih Gökbalp
14:35 - 14:50	Surgical Therapeutic Role for Node-Positive Disease: Does It Make a Difference? Dr. Deniz Bolat
14:50 - 15:05	Total Clinical Response: Now What? Dr. Yüksel Ürün
15:05 - 15:20	Biology of Tumor Types: Radiation Versus Surgery Dr. Ozan Cem Güler
15:20 - 15:30	Utility of Fluoro-deoxy-glucose Positron Emission Tomography (FDG-PET) to Predict a Pelvic Lymph Node Involvement (LNI) in Patients (pts) With muscle-invasive Bladder Cancer (MIBC) Enrolled in Neoadjuvant Therapy Trials. Dr. İsa Burak Güney
15:30 - 16:00	KAHVE MOLASI
16:00 - 17:05	Böbrek Kanseri Oturumu Dr. Yıldırım Bayazıt, Dr. Talha Müezzinoğlu
16:00 - 16:15	Parsiyel Nefrektomide 2024 Güncellemesi Dr. Volkan İzol
16:15 - 16:35	Role of Radiation in Primary Tumor and Distant Sites in Managing Renal Cell Carcinoma Dr. Fundagül Andıç
16:35 - 16:50	The Emergent Role of Theranostics in Renal Cell Carcinoma Dr. Mehmet Reyhan
16:50 - 17:05	Update on Biomarkers in Renal Cell Carcinoma Dr. Alp Özkan






ASCO GU 2024

Güncelleme

24-25 Mayıs 2024

Double Tree by Hilton, Adana



İkinci Gün 25 Mayıs 2024 Cumartesi	
09:00 - 09:55	Böbrek Kanseri Oturumu Oturum Başkanları: Dr. Süleyman Ataus, Dr. Özgür Yaycıoğlu
09:00 - 09:15	Böbrek Kanseri Patoloji Güncellemesi Dr. Yasemin Yuyucu Karabulut
09:15 - 09:20	Case Presentation Dr. Evren Süer
09:20 - 09:30	Genetic Testing: Who, When and How? Dr. Fehmi Narter
09:30 - 09:40	The Impact of Immunotherapy-Based Regimens in Primary Renal Tumors Dr. Oğuz Kara
09:40 - 09:50	Management of Non-Clear Cell Renal Cell Carcinoma Dr. Tolga Köşeci
09:50 - 09:55	Updated Case Presentation Dr. Evren Süer
10:00 - 10:30	KAHVE MOLASI
10:30 - 12:00	Prostat Kanseri Oturumu Oturum Başkanları: Dr. Can Öbek, Dr. Uğur Selek
10:30 - 10:40	Prostat Kanseri Minimal İnvaziv Yaklaşımda Son Durum Dr. Ender Özden
10:40 - 10:47	Setting the Stage: Biochemical Recurrence After Local Treatment for Prostate Cancer Dr. Kamil Çam
10:47 - 11:02	Salvage Radiotherapy Options for Biochemical Recurrence After Local Treatment Dr. Hüseyin Cem Önal
11:02 - 11:17	Systemic Treatment of High-Risk Biochemical Recurrence Dr. Çağatay Arslan
Çapraz Ateş	
11:20 - 11:35	Renaming Gleason 3+3 (Grade Group 1): For Dr. İlker Tinay
11:35 - 11:50	Renaming Gleason 3+3 (Grade Group 1): Against Dr. Serdar Çelik
11:50 - 12:00	ARA






ASCO GU 2024

Güncelleme

24-25 Mayıs 2024

Double Tree by Hilton, Adana



12:00 - 12:45	Uydu Sempozyumu Dr. Levent Türkeri, Dr. Çağatay Arslan
12:45 - 14:00	ÖĞLE YEMEĞİ
14:00 - 14:45	Prostat Kanseri Oturumu Oturum Başkanları: Dr. Çağ Çal, Dr. Barış Kuzgunbay
14:00 - 14:05	Case Presentation Dr. Mutlu Değer
14:05 - 14:15	Sequencing Hormonal Therapies After Treatment Intensification Dr. Ertuğrul Bayram
14:15 - 14:25	PSMA-Targeting and Radium-223
14:25 - 14:35	Relative Efficacy of Androgen Receptor Targeting Plus PARP Inhibition Dr. Berna Bozkurt
14:35 - 14:45	Is There a Role for Stereotactic Radiotherapy in Selected Patients With Metastatic Castrate-Resistant Prostate Cancer?
14:45 - 15:45	Mesane Kanseri Oturumu Oturum Başkanları: Dr. Sümer Baltacı, Dr. Sadık Görür
14:45 - 15:05	Harnessing the Power: Biologic Basis of Pairing and Sequencing Checkpoints With Other Therapy Dr. Mustafa Erman
15:05-15:20	Drug Sequencing, Pairing, Switching, and the Role of Checkpoint Rechallenging Dr. Berksoy Şahin
15:20 - 15:35	Lessons Learned: What Can Other Disease Sites Teach Us About Practical Implications of Checkpoint Therapy in Urothelial Carcinoma? Dr. Fatih Köse
15:35 - 15:45	Estimating the Impact of Adjuvant Treatment with Nivolumab on Long-term Survivorship Rates Compared with Surveillance Dr. Cem Mirili
16:00	KAPANIŞ

